Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology - PubMed (original) (raw)
Review
Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology
Claudia A Dumitru et al. Cancer Immunol Immunother. 2012 Aug.
Abstract
Accumulating evidence indicates that myeloid cells are critically involved in the pathophysiology of human cancers. In contrast to the well-characterized tumor-associated macrophages, the significance of granulocytes in cancer has only recently begun to emerge. A number of studies found increased numbers of neutrophil granulocytes and granulocytic myeloid-derived suppressor cells (GrMDSCs) both in the peripheral blood and in the tumor tissues of patients with different types of cancer. Most importantly, granulocytes have been linked to poor clinical outcome in cancer patients which suggests that these cells might have important tumor-promoting effects. In this review, we will address in detail the following major topics: (1) neutrophils and GrMDSCs in the peripheral blood of cancer patients-phenotype and functional changes; (2) neutrophils and GrMDSCs in the tumor tissue-potential mechanisms of tumor progression and (3) relevance of neutrophils and GrMDSCs for the clinical outcome of cancer patients. Furthermore, we will discuss the advantages and disadvantages of the current strategies used for identification and monitoring of human MDSCs. We propose a six-color immunophenotyping protocol that discriminates between monocytic MDSCs (MoMDSCs), two subsets of GrMDSCs and two subsets of immature myeloid cells in human cancer patients, thus, allowing for an improved characterization and understanding of these multifaceted cells.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Fig. 1
Proposed immunophenotyping scheme for MDSC discrimination by flow cytometry. PBMC were isolated from fresh blood samples by density gradient centrifugation and stained for the indicated markers. CD33 distinguishes myeloid cells from non-myeloid cells. MoMDSCs are identified by the monocytic marker CD14, high expression of CD33 (CD33+) and low expression of HLA-DR (HLA-DRlow). HLA-DRnegCD33dim cells are divided into CD66bneg ImMC and CD66b+ GrMDSC. CD16 and CD11b are used to differentiate between subsets of GrMDSC, namely immature CD11bneg and/or CD16neg and mature activated CD16+CD11b+ GrMDSC. Please note that, similar to GrMDSC, also CD33dimHLA-DRnegCD66bneg cells consist of CD11b+ and CD11bneg cells. Conclusion: CD14, CD66b, CD33 and HLA-DR are required to define MoMDSCs, GrMDSCs and ImMCs, CD11b and CD16 are useful to define further subsets
Similar articles
- On the origin of myeloid-derived suppressor cells.
Millrud CR, Bergenfelz C, Leandersson K. Millrud CR, et al. Oncotarget. 2017 Jan 10;8(2):3649-3665. doi: 10.18632/oncotarget.12278. Oncotarget. 2017. PMID: 27690299 Free PMC article. Review. - Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression.
Dumitru CA, Lang S, Brandau S. Dumitru CA, et al. Semin Cancer Biol. 2013 Jun;23(3):141-8. doi: 10.1016/j.semcancer.2013.02.005. Epub 2013 Feb 26. Semin Cancer Biol. 2013. PMID: 23485549 Review. - Granulocytic subset of myeloid derived suppressor cells in rats with mammary carcinoma.
Dolen Y, Gunaydin G, Esendagli G, Guc D. Dolen Y, et al. Cell Immunol. 2015 May;295(1):29-35. doi: 10.1016/j.cellimm.2015.02.005. Epub 2015 Feb 18. Cell Immunol. 2015. PMID: 25732602 - Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients.
Marini O, Spina C, Mimiola E, Cassaro A, Malerba G, Todeschini G, Perbellini O, Scupoli M, Carli G, Facchinelli D, Cassatella M, Scapini P, Tecchio C. Marini O, et al. Oncotarget. 2016 May 10;7(19):27676-88. doi: 10.18632/oncotarget.8507. Oncotarget. 2016. PMID: 27050283 Free PMC article. - Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients.
Jordan KR, Kapoor P, Spongberg E, Tobin RP, Gao D, Borges VF, McCarter MD. Jordan KR, et al. Cancer Immunol Immunother. 2017 Apr;66(4):503-513. doi: 10.1007/s00262-016-1953-z. Epub 2017 Jan 20. Cancer Immunol Immunother. 2017. PMID: 28108766 Free PMC article.
Cited by
- Potential Association of Maker Expression of Low-Density Neutrophils and Their Phenotypes in Patients with Periodontitis: Control Study.
Mousa AO, Al Hussaini AHA. Mousa AO, et al. Biomed Res Int. 2024 Jun 6;2024:5498307. doi: 10.1155/2024/5498307. eCollection 2024. Biomed Res Int. 2024. PMID: 39376254 Free PMC article. - The impact of the tumor microenvironment on the survival of penile cancer patients.
Lohse S, Mink JN, Eckhart L, Hans MC, Jusufi L, Zwick A, Mohr T, Bley IA, Khalmurzaev O, Matveev VB, Loertzer P, Pryalukhin A, Hartmann A, Geppert CI, Loertzer H, Wunderlich H, Lenhof HP, Naumann CM, Kalthoff H, Junker K. Lohse S, et al. Sci Rep. 2024 Sep 27;14(1):22050. doi: 10.1038/s41598-024-70855-z. Sci Rep. 2024. PMID: 39333233 Free PMC article. - The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors.
Miao S, Rodriguez BL, Gibbons DL. Miao S, et al. Cancers (Basel). 2024 Jul 10;16(14):2507. doi: 10.3390/cancers16142507. Cancers (Basel). 2024. PMID: 39061147 Free PMC article. Review. - Myeloid‑derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in colorectal cancer (Review).
Zeng W, Liu H, Mao Y, Jiang S, Yi H, Zhang Z, Wang M, Zong Z. Zeng W, et al. Int J Oncol. 2024 Sep;65(3):85. doi: 10.3892/ijo.2024.5673. Epub 2024 Jul 26. Int J Oncol. 2024. PMID: 39054950 Free PMC article. Review.
References
- Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol. 2007;25:1562–1569. doi: 10.1200/JCO.2006.09.0274. - DOI - PubMed
- Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, Nakano K, Tsuboi M, Shibata K, Furuse K, Fukushima M. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer. 2009;45:1950–1958. doi: 10.1016/j.ejca.2009.01.023. - DOI - PubMed
- Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, Stolz DB, Land SR, Marconcini LA, Kliment CR, Jenkins KM, Beaulieu KA, Mouded M, Frank SJ, Wong KK, Shapiro SD. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med. 2010;16:219–223. doi: 10.1038/nm.2084. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources